Ribozyme therapy for HIV infection.
Ribozyme therapy for HIV infection.
复制标题
HIV感染的核酶疗法。
DOI：
10.1016/s0169-409x(00)00085-5
复制
发表时间：
2000
影响因子：
16.1
通讯作者：
Rossi,JJ
中科院分区：
文献类型：
--
作者：
Rossi,JJ
在过去的几年中，在HIV-1感染的治疗方面取得了令人鼓舞的进展，这主要是由于HIV-1蛋白酶抑制剂与核苷和非核苷逆转录酶抑制剂的联合使用。尽管如此，HIV-1感染仍然是一个主要的全球性问题，并且耐药病毒的出现一直存在。持续需要开发新的治疗策略以及改进用于治疗这种病毒感染的所有形式的现有疗法。自从第一次证明核酶可以有效地抑制细胞培养中的HIV-1感染性传播以来，已经过去了将近十年。从那时起，核酶主要通过基因治疗方法进入人类临床试验。这一进展使核酶成为日益增长的抗HIV-1武器库的重要补充。本文综述了近10年来抗HIV-1核酶的研究进展，并对以抑制HIV-1感染为目的的核酶的研究现状进行了总结。
Within the past few years encouraging progress has been made in the treatment of HIV-1 infection, largely due to the combined use of HIV-1 protease inhibitors with nucleoside and non-nucleoside reverse transcriptase inhibitors. Despite this, HIV-1 infection is still a major global problem and the emergence of a drug resistant virus is ever present. There is a continuing need to develop new therapeutic strategies as well as improve upon all forms of existing therapies for the treatment of this viral infection. It has now been almost a decade since the first demonstration that ribozymes can effectively inhibit HIV-1 infectious spread in cell culture. Since then, ribozymes have progressed into human clinical trials primarily through gene therapy approaches. This progression brings ribozymes into the forefront as an important addition to the growing arsenal of anti-HIV-1 weapons. The following review covers the developments in anti-HIV-1 ribozyme usage over the past decade and summarizes the current state of ribozyme development for the purpose of inhibiting HIV-1 infection.